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esponsibility of Inst
ess under CC BY-NC-Abstract Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several
DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8
(DPP8) and dipeptidyl peptidase 9 (DPP9) share high sequence and structural homology as well as
functional activity with DPP4. However, the inhibition of their activities was reported to cause severe
toxicities. Thus, the development of DPP4 inhibitors that do not have DPP8 and DPP9 inhibitory activity is
critical for safe anti-diabetic therapy. To achieve this goal, we established a selective evaluation method for
DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins expressed by Rosetta cells. In this
method, we used puriﬁed recombinant 120 kDa DPP8 or DPP9 protein from the Rosetta expression system.
The optimum concentrations of the recombinant DPP8 and DPP9 proteins were 30 ng/mL and 20 ng/mL,
respectively, and the corresponding concentrations of their substrates were both 0.2 mmol/L. This method
was highly reproducible and reliable for the evaluation of the DPP8 and DPP9 selectivity for DPP4 inhibitor
candidates, which would provide valuable guidance in the development of safe DPP4 inhibitors.
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Dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9)
belong to the S9b gene family (also called the ‘DPP4 gene family’),
which share sequence homology, a similar tertiary structure and
functional activity with dipeptidyl peptidase 4 (DPP4)1. Considering
the post-proline dipeptidyl aminopeptidase activity of the S9b gene
family, various neuropeptides, chemokines, and peptide hormones
can be their natural substrates and be involved in their protein
degradation2. Therefore, many of these enzymes have been found to
be effective drug targets. For example, DPP4 is a target of type 2
diabetes. By extending the half-life of endogenous glucagon-like
peptide-1 (GLP-1), DPP4 inhibitors can induce insulin secretion,
lower blood glucose and HbA1C levels, reduce the apoptosis and
improve the proliferation of β cells. Five DPP4 inhibitors, sitagliptin,
valdagliptin, saxaglptin, alogliptin and linagliptin, have been on the
market3.
The safety or side effects of DPP4 inhibitors are the key points
of consideration during drug discovery, mainly due to the
similarity of DPP8/9 with DPP4. The amino acid sequences of
DPP8 and DPP9 are highly identical to DPP44,5. All three proteins
also share similar structures, consisting of an N-terminal, eight-
bladed β-propeller, C-terminal α/β hydrolase domain6, a catalytic
triad (Ser–Asp–His) and a conserved Glu motif (Glu–Glu)7.
Currently, little is known about the endogenous substrates and
biological functions of DPP8 and DPP9, but some studies have
indicated that selective DPP8 and DPP9 inhibitors may cause
severe toxicities, such as thrombocytopenia, alopecia, reticulocy-
topoenia, enlarged lymph nodes, splenomegaly, multiorgan histo-
pathological changes and mortality in rats and gastrointestinal
toxicity in dogs. Inhibition of DPP8 and DPP9 activities may
attenuate T cells activation and proliferation in vitro8. So without
DPP8 and DPP9 inhibitory activity is very important to the
development of a DPP4 inhibitor as an anti-diabetic agent.
This study was to establish an evaluation method based on
recombinant human DPP8 and DPP9 proteins to detect the
selectivity of DPP4 inhibitor candidates, which would provide
valuable guidance in the development of safe DPP4 inhibitors.2. Materials and methods
2.1. Chemicals and reagents
The recognised dipeptidyl peptidase (DPP) substrate Gly-Pro-p-
nitroanilide and DPP4 enzyme were purchased from Sigma
(Missouri, USA). The VigoScript ﬁrst strand cDNA synthesis kit
was a product of Vigorous (Beijing, China). Rosetta competent
cells were obtained from TransGen (Beijing, China). Restriction
enzymes were purchased from Takara (Dalian, China). Nickel
afﬁnity columns, Trizol reagent and DNA polymerase were
obtained from Invitrogen (Shanghai, China). The plasmid vector
pET32-a(þ) was a product of Novagen (Shanghai, China). The
anti-His antibody was purchased from Abmart (Shanghai, China).
The DPP inhibitor compounds, sitagliptin and UAMC00132 were
provided by Prof. Haihong Huang.
2.2. Cloning and construction of recombinant DPP8 and DPP9
The full-length fragments of human DPP8 and DPP9 were obtained via
reverse-transcription (RT)–PCR technology from HeLa and HepG2
cells, respectively. Primers for human DPP8 (GenBank ID: AF221634;DPP8-Forward-Hind III 50-ATCAAGCTTGCCACCATGGCAGC-
AGCAATG-30 and DPP8-Reverse-Sal I 50-ATCGTCGACTTATA-
TCACTTTTAGAGCAGCAATACG-30) and DPP9 (GenBank ID:
AF374518; DPP9-Forward-BamH I 50-ATCGGATCCGCCACCAT-
GGGGAAGGTTAAG-30 and DPP9-Reverse-Xho I 50-ATCCTCGA-
GTCAGAGGTATTCCTGTAGAAAGTGCAG-30) were designed
with restriction enzyme sites for directional cloning. The PCR was
performed as follows: DNA denaturation at 94 1C for 10 min, then 35
cycles (94 1C for 10 s, 65.8 1C for 30 s, 72 1C for 3 min) and a ﬁnal
extension at 72 1C for 10 min. The Hind III/Sal I fragment of DPP8
was subcloned into the Hind III and Xho I digested pET32-a(þ)
expression vector, generating plasmid pET32-a(þ)–DPP8. Meanwhile,
the BamH I/Xho I fragment of DPP9 was subcloned into the BamH I
and Xho I digested pET32-a(þ) expression vector, generating plasmid
pET32-a(þ)–DPP9. Finally, their sequences were veriﬁed. pET32-a
(þ)–DPP8 and pET32-a(þ)–DPP9 were expected to express recombi-
nant DPP8 and DPP9 proteins containing 882 and 892 amino acids,
respectively, with additional His6, S and Trx tags in the N-terminus.
2.3. Prokaryotic expression, protein puriﬁcation and Western blot
Rosetta competent cells transformed with the pET32-a(þ)–DPP8
plasmid were cultured in LB medium containing 50 μg/mL ampicillin
at 37 1C. Protein expression was induced by isopropyl β-D-thiogalac-
topyranoside (IPTG) (1 mmol/L) at 16 1C for 20 h, until the OD600
value of the LB medium reached 0.6. The cells were harvested at
6000 rpm for 5 min and incubated in lysozyme buffer (2 mg/mL
lysozyme, 100 mmol/L Tris–HCl pH 7.4, 100 mmol/L NaCl) for
40 min on ice. This was followed by centrifugation at 12,000 rpm for
10 min and ﬁltration through a 0.45 μm ﬁlter. The ﬁltrate was puriﬁed
with a nickel afﬁnity column as follow: the column was equilibrated
with binding buffer (20 mmol/L Tris–HCl pH 7.9, 10 mmol/L
imidazole, 0.5 mol/L NaCl), and then the supernatant was passed
through the column. Subsequently, binding buffer was used to wash
the column, followed by elution buffer (20 mmol/L Tris–HCl pH 7.9,
500 mmol/L imidazole, 0.5 mol/L NaCl). All procedures were done at
4 1C. The enzyme activities of the eluted fractions were monitored, and
the active fractions were pooled and analysed using sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blot. The expression and puriﬁcation procedures of DPP9 were the
same as DPP8.
2.4. Determination of the optimum concentrations of the substrate
and puriﬁed recombinant proteins
To determine the optimum concentrations of the substrate and
puriﬁed recombinant proteins, the assay was performed with
different concentrations of DPP8 or DPP9 protein (0–60 ng/mL)
and a concentration range of Gly-Pro-p-nitroanilide (0–0.5 mmol/
L) in HEPES buffer (pH 7.05) in a ﬁnal volume of 100 mL. The
change in absorbance at 405 nm was kinetically monitored every
10 min for 120 min at 37 1C.
2.5. DPP selectivity evaluation based on DPP8/9 and DPP4
inhibitor screening method
2.5.1. DPP selectivity evaluation based on DPP8/9 inhibition
assays
For the practicality and applicability of the inhibition assays, the
proven DPP4 inhibition assay was referenced, which indicated the
changes of OD values were 0.1–0.2 in 60 min. According to the
optimised concentration detection results described above, the ﬁnal
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chosen to be 10 μmol/L and 0.2 mmol/L, respectively; and the
concentrations of DPP8 and DPP9 were 30 ng/mL and 20 ng/mL,
respectively. The change in absorbance at 405 nm was monitored
for 60 min at 37 1C. Distilled water was used as a negative control.
The percentage of inhibition was calculated as shown below.
Inhibition (%)¼ (ΔOD60-0 of controlΔOD60-0 of test)/ΔOD60-0
of control 100%
2.5.2. The screening method of DPP4 inhibitor
The test well contained 10 mL compound solution (diluted to the
concentration of 10 mmol/L) and 50 mL DPP4 solution (2 mU/mL
in 50 mmol/L Tris–HCl buffer, pH 8.0) in a 96-well plate. The
enzyme reaction was started by addition of 40 mL Gly-Pro-p-
nitroanilide solution (0.26 mmol/L, in HEPES buffer, pH 7.05).
The change in absorbance at 405 nm was monitored for 60 min at
37 1C. Compound solution was replaced by the distilled water in
the negative control well. The percent of inhibition was calculated
as above.
Two different DPP inhibitors, sitagliptin and UAMC00132,
were used to conﬁrm the speciﬁc inhibition of DPP8/9 and DPP4.
2.6. Statistical analysis
All values were presented as mean7S.E.M. The Sigma Plot
software was used for data analysis.3. Results
3.1. Construction of prokaryotic DPP8/9 expression plasmids
Using RT-PCR, we obtained 2649 bp and 2679 bp fragments of
DPP8 and DPP9, respectively, with extra primer bases (Fig. 1A).
Using the additional restriction sites, the DNA fragments were
successfully inserted into the pET32-a(þ) (5,900 bp) plasmid
and identiﬁed by restriction digestion (Fig. 1B and C) and
sequencing.
3.2. Protein expression, puriﬁcation and identiﬁcation
The recombinant human DPP8 and DPP9 proteins were success-
fully expressed in the Rosetta cells induced by IPTG (1 mmol/L)
and analysed by SDS-PAGE. The corresponding bands of DPP8Figure 1 Identiﬁcation of the recombinant plasmids by restriction digesti
DPP8; Line 2: DPP9. (B) Identiﬁcation of the recombinant pET32-a(þ)–DP
Identiﬁcation of the recombinant pET32-a(þ)–DPP9 plasmid. M: DNA mand DPP9 were both at approximately 120 kDa (Fig. 2A and C).
The recombinant DPP8 and DPP9 proteins with His6-tags were
puriﬁed on a nickel afﬁnity column and then dissolved in the
neutral Tris buffer. The soluble, puriﬁed target proteins were
also approximately 120 kDa (Fig. 2B and D), which was con-
ﬁrmed by Western blot analysis using an anti-His antibody
(Fig. 2E and F).3.3. Determination of the optimum concentrations of DPP8/9
and substrate in a direct enzyme inhibition assay
The recombinant human DPP8 and DPP9 proteins were found to
display speciﬁc dipeptidyl peptidase activities similar to DPP4, but
the enzyme kinetic characteristics were unknown. By monitoring
the increasing absorbance rate at 405 nm, concentration-activity
experiments of recombinant DPP8/9 were performed. The experi-
ment showed that the reactivity of recombinant DPP9 was higher
than DPP8. To determine the reliable and practical reaction
conditions that were suitable for the soluble DPP8 and DPP9
activity inhibition assay, the proven DPP4 inhibition assay was
referenced, which indicated the changes of OD values were 0.1–
0.2 in 60 min. The experiment indicated that the optimum
concentrations of the puriﬁed recombinant DPP8 and DPP9
proteins were 30 ng/mL and 20 ng/mL for 60 min, respectively,
with 0.5 mmol/L substrate (Fig. 3A and B), and the optimum
substrate concentration for both DPP8 (30 ng/mL) and DPP9
(20 ng/mL) was 0.2 mmol/L (Fig. 3C and D).3.4. DPP inhibition selectivity evaluation based on a direct
DPP8/9 and DPP4 enzyme inhibition assay
Using the recombinant DPP8/9 activity assay with the above
optimised reaction conditions and the DPP4 activity assay method,
the effects of two reported DPP inhibitors on DPP8/9 and DPP4
activities were determined. DPP8/9 inhibitor UAMC00132
(10 μmol/L) could, while DPP4 inhibitor sitagliptin (10 μmol/L)
could not, inhibit DPP8 and DPP9 activities. Meanwhile, sitagliptin
strongly inhibited DPP4 activity strongly, while UAMC00132 only
slightly inhibited DPP4 activity (Fig. 4), which indicated that the
selective evaluation method was established to evaluate the DPP8
and DPP9 selectivity of DPP4 inhibitor candidates.on. (A) RT-PCR of human DPP8 and DPP9. M: DNA marker; Line 1:
P8 plasmid. M: DNA marker; Line 1: pET32-a(þ)–DPP8 plasmid. (C)
arker; Line 1: pET32-a(þ)–DPP9 plasmid.
Figure 2 SDS-PAGE and Western blot analyses of recombinant DPP8 and DPP9 proteins. (A) Expression of DPP8 protein. M: protein marker; Line 1:
negative control without induction by IPTG; Line 2: the expression of recombinant DPP8 protein induced by IPTG; (B) Puriﬁcation of DPP8 protein. M:
protein marker; Line 1: recombinant DPP8 protein puriﬁed using a nickel afﬁnity column. (C) Expression of DPP9 protein. M: protein marker; Line 1:
negative control without induction by IPTG; Line 2: the expression of recombinant DPP9 protein induced by IPTG; (D) Puriﬁcation of DPP9 protein. M:
protein marker; Line 1: recombinant DPP9 protein puriﬁed using a nickel afﬁnity column. (E) Western blot analysis of puriﬁed DPP8 protein using an anti-
His antibody. (F) Western blot analysis of puriﬁed DPP9 protein using an anti-His antibody. The arrow marks the corresponding recombinant protein at
approximately 120 kDa.
Figure 3 Determination of the optimum concentrations of the puriﬁed recombinant DPP8/9 protein and substrate. The puriﬁed recombinant DPP8 (A) and
DPP9 (B) proteins, with a range of concentrations from 0 to 60 ng/mL and 0.5 mmol/L substrate; The substrate with different concentrations, from 0.05 to
0.5 mmol/L at 30 ng/mL DPP8 (C) and 20 ng/mL DPP9 (D).
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Figure 4 Inhibition of recombinant DPP8/9 and DPP4 activities by UAMC00132 and Sitagliptin. Chemical structure of UAMC00132 (A) and
sitagliptin (B). (C) The DPP8/9 and DPP4 inhibitory activities of sitagliptin and UAMC00132. In DPP8/9 inhibition assays, 30 ng/mL puriﬁed
DPP8 protein or 20 ng/mL puriﬁed DPP9 protein and 0.2 mmol/L substrate were used, and in DPP4 inhibition assay, 1 mU/mL DPP4 protein and
0.1 mmol/L substrate were used. The result was presented as the percentage of enzyme activity inhibition.
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The two DPP4 homologues, DPP8 and DPP9, were identiﬁed in
the years 20004 and 20025. Especially Lankas et al.8 found that
the inhibition of DPP8 and DPP9 activities could cause severe
toxicities. Since then, DPP8 and DPP9 have become popular
issues, and a great deal of attentions have been focused on the
genes, substrates, inhibitors, structures and functions of these
peptidases. In this study, we established a selective evaluation
method of DPP4 inhibitors based on the recombinant human DPP8
and DPP9 proteins, which would facilitate and accelerate ﬁnding
potent and highly selective DPP4 inhibitors.
We used Rosetta cells to express the full length 882 amino acid
DPP8 (DPP8882aa) and 892 amino acid DPP9 (DPP9892aa) proteins
with additional His6, S and Trx tags in the N-terminus and with or
without another His6-tag in the C-terminus. In these recombinant
variants, we found that only the full length DPP8 and DPP9
proteins without the C-terminus His6-tag had enzymatic activities,
which was consistent with a report by Bjelke9. Some reports
showed that the puriﬁed recombinant DPP8 and DPP9 proteins
were monomeric when C-terminus tags were present, but when
tags were in the N-terminus, the protein could be dimeric4,7,9.
As dimerisation was shown to be essential for the peptidase
activity, we considered that the C-terminus His6-tag of recombi-
nant DPP8/9 may prevent dimerisation and cause a loss of activity.
Conversely, other studies have reported active DPP9 with a
C-terminus His6-tag expressing in a eukaryotic system, such as
Pichia pastoris and Spodoptera frugiperda 9 (Sf9) cells, and
assumed that the presence of post-translational modiﬁcations in
mammalian cells may inﬂuence the activity of recombinant
DPP910–14. In this study, active recombinant DPP8/9 with an
N-terminal His6-tag, ﬁrst expressing in a prokaryotic system,
showed practical and suitable activity for use in a DPP
inhibitor assay.
The Glu–Glu motif in DPP4 (Glu205–Glu206) was also present
in DPP8 (Glu256–Glu257) and DPP9 (Glu277–Glu278), which was
very important to the peptidase activity and substrate entry, and
any mutation in this motif would abolish the peptidase activity7,15.Some reports also suggested that the α/β hydrolase domains in
both the N- and C-terminus of DPP8 and DPP9 proteins were
pivotal to the enzymatic activity and to maintain an intact structure
and removing these domains would abolish the enzymatic
activity7. We also expressed the truncated Δ659–882 amino acid
of DPP8 (DPP8Δ659–882aa) with additional His6, S and Trx tags in
the N-terminus. We further conﬁrmed that the lack of the Glu–Glu
motif and the α/β hydrolase domain of the N-terminus completely
abolished enzymatic activity, even though DPP8Δ659–882aa con-
tained the catalytic domain.
In summary, we had established a selective evaluation method for
DPP4 inhibitor candidates based on the recombinant human DPP8
and DPP9 proteins. This method was highly reproducible and reliable
and would provide valuable guidance in the development of
promising selective and safe DPP4 inhibitors. We had used the
method to evaluate a number of DPP4 inhibitor candidates.
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